Enhancing precision in pain management for inflammatory arthritis: exploring the potential role of lidocaine in pain mechanism differentiation

Letter to the Editor: Chronic pain is common in patients with inflammatory arthritis (IA), driven by both peripheral joint inflammation and sustained central sensitization. Although anti-inflammatory treatments can alleviate some symptoms, many patients continue to experience persistent pain, highlighting the significant role of central pain processing mechanisms.2 Accurate identification and differentiation between peripheral and central pain mechanisms are essential for developing targeted treatment plans because these 2 pathways respond differently to treatments and affect long-term pain management strategies.4 Currently, standardized tools to precisely distinguish these mechanisms are lacking, especially considering that approximately 40% of patients with IA may experience central sensitization, which directly affects their quality of life and clinical outcomes.1 Therefore, establishing an effective and practical clinical method to assess and differentiate pain mechanisms would not only facilitate personalized treatment approaches but also offer new perspectives for enhancing pain management in patients with IA. We read with great interest the study by Rutter-Locher et al.3 and commend the authors on their contributions to this field. This randomized controlled trial on patients with inflammatory arthritis explores the potential use of intra-articular lidocaine to differentiate between central and peripheral pain mechanisms. Using a multilevel assessment incorporating baseline pain scores, the pain DETECT questionnaire, and fibromyalgia criteria, the authors quantified the immediate analgesic effects of lidocaine while also identifying characteristics of patients with central sensitization, particularly in those with high pain scores. The findings suggest that lidocaine's pain relief is less effective in patients with a higher degree of centrally mediated pain, indicating its effects may rely more on peripheral mechanisms. This provides valuable clinical evidence for more precise, stratified management of pain in patients with IA. By advancing a potential diagnostic tool for pain stratification and personalized management in IA, the authors have paved the way for future developments in this area. Although the study represents significant progress, certain aspects warrant further investigation and refinement. First, the limited sample size may affect the external validity of the study's findings, especially when conducting subgroup analyses; an insufficient sample may reduce statistical power, potentially obscuring clinically meaningful differences. In addition, the study observed pain changes only within 10 minutes after lidocaine injection, without assessing longer-term effects. Given the dynamic nature of pain mechanisms, such a short observation period may not fully capture the complexity of centrally mediated pain. Furthermore, the study did not adequately control for multifactorial variables that significantly affect pain perception, such as chronic comorbidities and psychological factors (eg, anxiety and depression), which may play a critical role in the development of central sensitization pain. In future studies, increasing sample size and incorporating multicenter data collection will be essential for enhancing the external validity and generalizability of the findings across diverse populations. A larger sample will enable more precise subgroup analyses, allowing a clearer understanding of how lidocaine specifically affects central and peripheral pain mechanisms in different patient subsets. Extending the observation period to assess the long-term effects of lidocaine injections will also provide insights into the dynamic nature of pain mechanisms and the persistence of central sensitization, supporting a more comprehensive evaluation of treatment outcomes. To control for multifactorial influences, future study designs should include assessments of common comorbidities and psychological factors (such as anxiety and depression), reducing potential confounding effects and allowing for a more accurate interpretation of lidocaine's role in distinguishing pain mechanisms. In addition, integrating other pain assessment tools or biomarkers, such as functional MRI and quantitative sensory testing (QST), could aid in verifying the classification of pain mechanisms. This multimodal approach would not only support further validation of intra-articular lidocaine's clinical utility but also advance mechanism-based personalized pain management, facilitating more precise diagnosis and treatment. Conflict of interest statement The authors have no conflicts of interest to declare.